Emerging drugs for bronchiectasis

Expert Opinion on Emerging Drugs

Volumn 17, Issue 3, 2012, Pages 361-378

  Chang, Anne B ^a,b   Marsh, Robyn L ^b   Smith Vaughan, Heidi C ^b   Hoffman, Lucas R ^c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adults; Bronchiectasis; Children; Cough; Treatment

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; ERDOSTEINE; MANNITOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; SODIUM CHLORIDE;

AIRWAY; ANTICHOLINERGIC EFFECT; ASTHMA; BRONCHIECTASIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG HALF LIFE; DRUG MEGADOSE; HEALTH CARE COST; HUMAN; INCIDENCE; LUNG CLEARANCE; MEDICAL RESEARCH; MORBIDITY; NEBULIZATION; NUTRITION; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PREVALENCE; REVIEW; SINGLE DRUG DOSE; SMOKING CESSATION; SUPPLEMENTATION; TOBACCO; VACCINATION;

ADRENAL CORTEX HORMONES; ADULT; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; BRONCHODILATOR AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; EXPECTORANTS; HUMANS; MARKETING; TREATMENT OUTCOME;

EID: 84865612616     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.702755     Document Type: Review

References (196)

1. King P, Holdsworth S, Freezer N, Holmes P. Bronchiectasis. Intern Med J 2006;36(11):729-37 (Pubitemid 44563435)
2. King PT, Holdsworth SR, Freezer NJ, et al. Outcome in adult bronchiectasis. COPD 2005;2(1):27-34 (Pubitemid 40776219)
3. Chang AB, Masel JP, Boyce NC, et al. Non-CF bronchiectasis-clinical and HRCT evaluation. Pediatr Pulmonol 2003;35(6):477-83
4. Kapur N, Masters IB, Morris PS, et al. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2012;47(1):68-75
5. King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006;100(4):2183-9 (Pubitemid 44718391)
6. Schraufnagel EDe. Breathing in America: Diseases, Progress, and Hope. American Thoracic Society; 2010
7. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162(4):1277-84
8. Chang AB, Grimwood K, Macguire G, et al. Management of bronchiectasis and chronic suppurative lung disease (CSLD) in Indigenous children and adults from rural and remote Australian communities. Med J Aust 2008; 189(7):386-93
9. Silverman PM, Godwin JD. CT/bronchographic correlations in bronchiectasis. J Comput Assist Tomogr 1987;11(1):52-6 (Pubitemid 17231462)
10. Matsuoka S, Uchiyama K, Shima H, et al. Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. AJR Am J Roentgenol 2003;180(2):513-18 (Pubitemid 36135043)
11. Chang AB, Redding GJ, Everard ML. State of the Art-Chronic wet cough: protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol 2008;43(6):519-31 (Pubitemid 351813004)
12. Seitz AE, Olivier KN, Steiner CA, et al. Trends and Burden of Bronchiectasis-Associated Hospitalizations: USA, 1993-2006. Chest 2010;138(4):944-9
13. Santamaria F, Montella S, Pifferi M, et al. A descriptive study of non-cystic fibrosis bronchiectasis in a pediatric population from central and southern Italy. Respiration 2009;77(2):160-5
14. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12(4):205-9 (Pubitemid 41098340)
15. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010;104(7):981-5
16. Steinfort DP, Brady S, Weisinger HS, Einsiedel L. Bronchiectasis in Central Australia: a young face to an old disease. Respir Med 2008;102(4):574-8
17. Singleton RJ, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000;29(3):182-7 (Pubitemid 30141794)
18. Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 2008;7(5):450-3
19. Chang AB. Editorial. Bronchiectasis: so much yet to learn and to do. Paediatr Respir Rev 2011;12:89-90
20. Available from: www.cff.org/AboutCF/Faqs [Accessed 24 Dec 2010]
21. Twiss J, Metcalfe R, Edwards EA, Byrnes C. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child 2005;90(7):737-40 (Pubitemid 40922509)
22. O'Grady KA, Torzillo PJ, Chang AB. Hospitalisation of Indigenous children in the Northern Territory for lower respiratory illness in the first year of life. Med J Aust 2010;192(10):586-90
23. Kwak HJ, Moon JY, Choi YW, et al. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku J Exp Med 2010;222(4):237-42
24. Chang AB, Robertson CF, van Asperen PP, et al. Can a management pathway for chronic cough in children improve clinical outcomes: protocol for a multicentre evaluation. Trials 2010;11(1):103
25. Chang AB, Robertson CF, van Asperen PP, et al. A multi-centre study on chronic cough in children: burden and etiologies based on a standardized management pathway. Chest 2012. [Epub ahead of print]
26. Donnelly DE, Critchlow A, Everard ML. Outcomes in children treated for persistent bacterial bronchitis. Thorax 2007;62(1):80-4 (Pubitemid 46101770)
27. Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high resolution computed tomography scans in severe asthma. Chest 2009;136(6):1521-8
28. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55(8):635-42 (Pubitemid 30468217)
29. Martinez-Garcia MA, Soler-Cataluna JJ, Donat SY, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011;140(5):1130-7
30. Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest 2011;140(3):626-33
31. Montes de OM, Halbert RJ, Lopez MV, et al. Chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J 2012; Epub ahead of print
32. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: epidemiology. Thorax 2006;61(2):164-8
33. Guerra S, Sherrill DL, Venker C, et al. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax 2009;64(10):894-900
34. Chang AB, Byrnes CA, Everard ML. Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis. Paediatr Respir Rev 2011;12(2):97-103
35. Gaillard EA, Carty H, Heaf D, Smyth RL. Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs. Eur J Radiol 2003;47(3):215-20 (Pubitemid 36970082)
36. Irwin RS. Complications of cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129(1 Suppl):54S-58
37. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005;128(2):739-45 (Pubitemid 41140504)
38. Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995;108(4):955-61
39. Saynajakangas O, Keistinen T, Tuuponen T, Kivela SL. The course of childhood bronchiectasis: a case report and considerations of hospital use. Int J Circumpolar Health 1998;57(4):276-9
40. Kapur N, Masters IB, Chang AB. Exacerbations in non cystic fibrosis bronchiectasis: clinical features and investigations. Respir Med 2009;103(11):1681-7
41. Cochrane GM. Chronic bronchial sepsis and progressive lung damage. BMJ 1985;290(6474):1026-7 (Pubitemid 15109945)
42. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung 2006;35(1):58-65 (Pubitemid 43106636)
43. Cole PJ. Inflammation: a two edged sword. The model of bronchiectasis. Eur J Respir Dis Suppl 1986;147(1):6-15 (Pubitemid 16017382)
44. Simons L, Simons J, Friedlander Y, McCallum J. Chronic bronchitis and risk of coronary heart disease. Lancet 1996;348(9038):1388-9 (Pubitemid 26383794)
45. Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis : prospective results from a large population study. Circulation 2001;103(8):1064-70 (Pubitemid 32200178)
46. Hill SL, Burnett D, Hewetson KA, Stockley RA. The response of patients with purulent bronchiectasis to antibiotics for four months. Q J Med 1988;66(250):163-73
47. Erdem E, Ersu R, Karadag B, et al. Effect of night symptoms and disease severity on subjective sleep quality in children with non-cystic-fibrosis bronchiectasis. Pediatr Pulmonol 2011;46(9):919-26
48. O'Leary CJ, Wilson CB, Hansell DM, et al. Relationship between psychological well-being and lung health status in patients with bronchiectasis. Respir Med 2002;96(9):686-92
49. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34:843-9
50. Keistinen T, Saynajakangas O, Tuuponen T, Kivela SL. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J 1997;10(12):2784-7 (Pubitemid 28052788)
51. Dogru D, Nik-Ain A, Kiper N, et al. Bronchiectasis: the consequence of late diagnosis in chronic respiratory symptoms. J Trop Pediatr 2005; 51(6):362-5 (Pubitemid 43118422)
52. Haidopoulou K, Calder A, Jones A, et al. Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function. Pediatr Pulmonol 2009;44(7):669-75
53. Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009;33(2):312-18
54. Bastardo CM, Sonnappa S, Stanojevic S, et al. Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function. Thorax 2009;64(3):246-51
55. Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J 1997;10(10):2376-9 (Pubitemid 27479564)
56. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med 2008;14(6):595-9
57. Gharagozlou M, Ebrahimi FA, Farhoudi A, et al. Pulmonary complications in primary hypogammaglobulinemia: a survey by high resolution CT scan. Monaldi Arch Chest Dis 2006;65(2):69-74 (Pubitemid 44209756)
58. Karadag B, Karakoc F, Ersu R, et al. Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries. Respiration 2005;72(3):233-8 (Pubitemid 40981080)
59. Babayigit A, Olmez D, Uzuner N, et al. A neglected problem of developing countries: noncystic fibrosis bronchiectasis. Ann Thorac Med 2009;4(1):21-4
60. Hill SL, Morrison HM, Burnett D, Stockley RA. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax 1986;41(7):559-65 (Pubitemid 16070391)
61. Lin HC, Cheng HF, Wang CH, et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997;155(6):2024-9
62. Wilson CB, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10(8):1754-60 (Pubitemid 27368366)
63. Ip M, Shum D, Lauder I, et al. Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis. Respir Med 1993;87(6):449-54 (Pubitemid 23266353)
64. Currie DC, Garbett ND, Chan KL, et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990;76(280):799-816 (Pubitemid 20244071)
65. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127(4):1420-6 (Pubitemid 46224309)
66. Chang AB, Bell SC, Byrnes CA, et al. Bronchiectasis and chronic suppurative lung disease (CSLD) in children and adults in Australian and New Zealand: thoracic Society of Australia and New Zealand and Australian Lung Foundation Position Statement. Med J Aust 2010;193(6):356-65
67. Hare KM, Grimwood K, Leach AJ, et al. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian Indigenous children with bronchiectasis. J Pediatr 2010;157(6):1001-5
68. King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007;101(8):1633-8 (Pubitemid 46930715)
69. Kapur N, Grimwood K, Masters IB, et al. Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis. Pediatr Pulmonol 2012;47(3):300-7
70. Anwar GA, Bourke SC, Afolabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008;102(10):1494-6
71. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. Cochrane Database Syst Rev 2007;2:CD00512
72. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008;31(1):12-20 (Pubitemid 350236720)
73. Mutak S. Azalides from azithromycin to new azalide derivatives. J Antibiot (Tokyo) 2007;60(2):85-122
74. Chang AB, Grimwood K, White AV, et al. Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol. Trials 2011;12:94
75. Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005;4(2):117-22 (Pubitemid 40613959)
76. Bahous J, Cartier A, Pneau L, et al. Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult. Bull Eur Physiopathol Respir 1984;20(4):375-80 (Pubitemid 14029113)
77. Ip M, Lam WK, So SY, et al. Analysis of factors associated with bronchial hyperactivity to methacholine in bronchiectasis. Lung 1991; 169(1):43-51
78. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009;1:CD000996
79. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005;60(3):239-43 (Pubitemid 40380285)
80. Guran T, Ersu R, Karadag B, et al. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. J Clin Pharm Ther 2008;33(6):603-11
81. Twiss J, Stewart AW, Byrnes CA. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thorax 2006;61(5):414-18 (Pubitemid 43723325)
82. Franco F, Sheikh A, Greenstone M. Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev 2003(1):CD003572
83. Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev 2001(4):CD002155
84. Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012;141(2):461-8
85. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005;99(1):27-31 (Pubitemid 40017380)
86. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105(12):1831-5
87. Daviskas E, Anderson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005;10(1):46-56 (Pubitemid 40343762)
88. Crockett AJ, Cranston JM, Latimer KM, Alpers JH. Mucolytics for bronchiectasis. Cochrane Database Syst Rev 2001(1):CD001289
89. Jones AP, Wallis CE, Kearney CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003;3
90. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113(5):1329-34 (Pubitemid 28223825)
91. Crisafulli E, Coletti O, Costi S, et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clin Ther 2007;29(9):2001-9 (Pubitemid 350212798)
92. Fuschillo S, De FA, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008;31(2):396-406
93. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(5):1086-92
94. Patterson JE, Hewitt O, Kent L, et al. Acapella versus 'usual airway clearance' during acute exacerbation in bronchiectasis: a randomized crossover trial. Chron Respir Dis 2007;4(2):67-74 (Pubitemid 47121680)
95. Llewellyn-Jones CG, Johnson MM, Mitchell JL, et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995;8(9):1479-87
96. Kapur N, Chang A. Oral non steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007(4):CD006427
97. Pizzutto SJ, Upham JW, Yerkovich ST, Chang AB. Inhaled non-steroid antiinflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2010(4):CD007525
98. Katsura H, Ogata M, Kida K. Factors determining outcome in elderly patients with severe COPD on long-term domiciliary oxygen therapy. Monaldi Arch Chest Dis 2001;56(3):195-201 (Pubitemid 32951958)
99. Failla ML. Trace elements and host defense: recent advances and continuing challenges. J Nutr 2003; 133(5 Suppl 1):1443S-7S (Pubitemid 36548722)
100. Grant CC. Pneumonia in children: becoming harder to ignore. NZ Med J 1999;112(1095):345-7
101. Black RE. Therapeutic and preventive effects of zinc on serious childhood infectious diseases in developing countries. Am J Clin Nutr 1998;68(2 Suppl):476S-9S (Pubitemid 28355623)
102. Dudley L, Hussey G, Huskissen J, Kessow G. Vitamin A status, other risk factors and acute respiratory infection morbidity in children. S Afr Med J 1997;87(1):65-70 (Pubitemid 27101996)
103. Chang CC, Morris PS, Chang AB. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007(3):CD006218
104. Hovden AO, Cox RJ, Haaheim LR. Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients. Int J Chron Obstruct Pulmon Dis 2007;2(3):229-40 (Pubitemid 350110896)
105. Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009;2
106. Li JS, Peat JK, Xuan W, Berry G. Meta-analysis on the association between environmental tobacco smoke (ETS) exposure and the prevalence of lower respiratory tract infection in early childhood. Pediatr Pulmonol 1999;27(1):5-13 (Pubitemid 29063795)
107. Acharya D, Prasanna KS, Nair S, Rao RS. Acute respiratory infections in children: a community based longitudinal study in south India. Indian J Public Health 2003;47(1):7-13
108. Couriel JM. Passive smoking and the health of children. Thorax 1994;49(8):731-4 (Pubitemid 24250226)
109. Townsend MC, DuChene AG, Morgan J, Browner WS. Pulmonary function in relation to cigarette smoking and smoking cessation. MRFIT Research Group. Prev Med 1991;20(5):621-37
110. Cahill K, Ussher MH. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev 2011(3):CD005353
111. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011(2):CD006103
112. Jeffry Modell Centers Network. Economic Impact Study: Comparing Undiagnosed and Diagnosed Patients with Primary Immunodeficiencies. Available from: http://www info4pi org/scientific-publications/pdf/Economic-Impact-110107 pdf 2012 [Accessed 25 March 2012]
113. Lavery KA, O'Neill B, Parker M, et al. Expert patient self-management program versus usual care in bronchiectasis: a randomized controlled trial. Arch Phys Med Rehabil 2011;92(8):1194-201
114. Newcombe PA, Sheffield JK, Juniper EF, et al. Development of a parent-proxy quality-of-life chronic cough-specific questionnaire: clinical impact vs psychometric evaluations. Chest 2008;133(2):386-95 (Pubitemid 351272396)
115. Kapur N, Masters IB, Newcombe P, Chang AB. The burden of disease in pediatric non-cystic fibrosis bronchiectasis. Chest 2012;14(4): 1018-24
116. Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-CF bronchiectasis-what influences lung function stability? Chest 2010;138(1):158-64
117. Kapur N, Karadag B. Differences and similarities in non-CF BE between developing and affluent countries. Paediatr Respir Rev 2011;12(2):91-6
118. King PT, Holdsworth SR, Farmer M, et al. Phenotypes of adult bronchiectasis: onset of productive cough in childhood and adulthood. COPD 2009;6(2):130-6
119. Doeschl-Wilson AB, Davidson R, Conington J, et al. Implications of host genetic variation on the risk and prevalence of infectious diseases transmitted through the environment. Genetics 2011;188(3):683-93
120. Chang AB, Yerkovich ST, Gibson PG, et al. Pulmonary innate immunity in children with protracted bacterial bronchitis. J Pediatr 2012;In press
121. Chang AB, Bilton D. Non-cystic fibrosis bronchiectasis exacerbations. Thorax 2008;63(3):269-76
122. Loebinger MR, Shoemark A, Berry M, et al. Procalcitonin in stable and unstable patients with bronchiectasis. Chron Respir Dis 2008;5(3): 155-60
123. Courtney JM, Kelly MG, Watt A, et al. Quality of life and inflammation in exacerbations of bronchiectasis. Chron Respir Dis 2008;5(3):161-8
124. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Bronchiectasis in Indigenous children in remote Australian communities. A position statement. Med J Aust 2002;177(4):200-4 (Pubitemid 35021432)
125. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1-i58
126. Lasserson T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev 2001(2):CD002163
127. Corless JA, Warburton CJ. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev 2000(2):CD002174
128. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2006(2):CD002996
129. Wurzel D, Marchant JM, Yerkovich ST, et al. Short courses of antibiotics for children and adults with bronchiectasis. Cochrane Database Syst Rev 2011(6):CD008695
130. Chang AB, Robertson CF, Grimwood K, et al. Randomised placebo-controlled trial on antibiotics for bronchiectasis exacerbations in children: rationale and protocol. Trials 2012;In press
131. Murray MP, Turnbull K, Macquarrie S, et al. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(1):125-31
132. Murray MP, Pentland JL, Turnbull K, et al. Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(2):361-4
133. Wilson R, Dowling RB, Jackson AD. The biology of bacterial colonization and invasion of the respiratory mucosa. Eur Respir J 1996;9(7):1523-30 (Pubitemid 26233800)
134. Slauson DO, Hahn FF. Criteria for development of animal models of diseases of the respiratory system: the comparative approach in respiratory disease model development. Am J Pathol 1980;101(3 Suppl):S103-22
135. McNeil C, Macgregor AR, Alexander WA. Studies of pneumonia in childhood: IV. Bronchiectasis and fibrosis of the lung. Arch Dis Child 1929;4:170-89
136. Finke W. Prospects for prevention of chronic bronchitis and bronchiectasis; rational management of bronchopulmonary infections by penicillin aerosol therapy. J Pediatr 1948;33(1):29-42
137. Field CE. Bronchiectasis in childhood; III. Prophylaxis, treatment and progress with a follow-up study of 202 cases of established bronchiectasis. Pediatrics 1949;4(3):355-72
138. Croxatto OC, Lanari A. Pathogenesis of bronchiectasis; experimental study and anatomic findings. J Thorac Surg 1954;27(5):514-28
139. Goeminne PC, Scheers H, Decraene A, et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012;13(1):21
140. Stockley RA. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. Thorax 1998;53(1):58-62 (Pubitemid 28178978)
141. Delarue JA, Abelanet RM. Pathogenesis of bronchiectasis; an experimental study. Dis Chest 1959;35(4):394-408
142. Field CE. Bronchiectasis in childhood: I. Clinical survey of 160 cases. Pediatrics 1949;4(1):21-46
143. Kobayashi H. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections. Treat Respir Med 2005;4(4):241-53 (Pubitemid 41252835)
144. Hall-Stoodley L, Hu FZ, Gieseke A, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006;296(2):202-11 (Pubitemid 44050374)
145. Chan TB, Arm JP, Anderson J, Eiser NM. Pulmonary epithelial permeability in bronchiectasis. Br J Dis Chest 1988;82(1):56-63 (Pubitemid 18034395)
146. Kapur N, Grimwood K, Masters IB, et al. Bronchoalveolar lavage fluid microbiology and airway cellularity in children newly diagnosed with bronchiectasis. Pediatric Pulmonol 2012;47(3):300-7
147. Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007;62(3):211-18 (Pubitemid 46579799)
148. Pizzutto SJ, Grimwood K, Bauert P, et al. Bronchoscopy contributes to the clinical management of Indigenous children newly doagnosed with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2012;In press
149. Ayars GH, Altman LC, Gleich GJ, et al. Eosinophil-and eosinophil granule-mediated pneumocyte injury. J Allergy Clin Immunol 1985;76(4):595-604 (Pubitemid 15245025)
150. Cowburn AS, Condliffe AM, Farahi N, et al. Advances in neutrophil biology: clinical implications. Chest 2008;134(3):606-12
151. Gernez Y, Tirouvanziam R, Chanez P. Neutrophils in chronic inflammatory airway diseases: can we target them and how? Eur Respir J 2010;35(3):467-9
152. Sabroe I, Whyte MK. Toll-like receptor (TLR)-based networks regulate neutrophilic inflammation in respiratory disease. Biochem Soc Trans 2007;35(Pt 6):1492-5
153. Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006;129(6):1673-82 (Pubitemid 43895000)
154. Hodge S, Hodge G, Scicchitano R, et al. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 2003;81(4):289-96 (Pubitemid 36904336)
155. Hodge S, Hodge G, Ahern J, et al. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2007;37(6):748-55 (Pubitemid 350211645)
156. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in COPD. Am J Respir Crit Care Med 2008;178:139-48 (Pubitemid 351957772)
157. Hodge S, Hodge G, Holmes M, Reynolds PN. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005;25(3):447-54 (Pubitemid 40331174)
158. Voglis S, Quinn K, Tullis E, et al. Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs. Am J Respir Crit Care Med 2009;180(2):159-66
159. Hodge S, Hodge G, Brozyna S, et al. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 2006;28(3):486-95 (Pubitemid 44794662)
160. Essilfie AT, Simpson JL, Horvat JC, et al. Haemophilus influenzae infection drives IL-17-mediated neutrophilic allergic airways disease. PLoS Pathog 2011;7(10):e1002244
161. Essilfie AT, Simpson JL, Dunkley ML, et al. Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax 2012. [Epub ahead of print]
162. Koskela HO, Purokivi MK, Romppanen J. Neurotrophins in chronic cough: association with asthma but not with cough severity. Clin Respir J 2010;4(1):45-50
163. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374(9691):733-43
164. Cheng KK. The experimental production of bronchiectasis in rats. J Pathol Bacteriol 1954;67(1):89-98
165. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007;52(9):1176-93
166. Lee AL, Button BM, Ellis S, et al. Clinical determinants of the 6-Minute Walk Test in bronchiectasis. Respir Med 2009;103(5):780-5
167. Daviskas E, Anderson SD, Eberl S, et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159(6):1843-8 (Pubitemid 29275053)
168. Daviskas E, Anderson SD, Young IH. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir Med 2010; Epub ahead of print
169. Anderson SD. Provocation challenges to help diagnose and monitor asthma: exercise, methacholine, adenosine and mannitol. Curr Opin Pulm Med 2008;14:39-45 (Pubitemid 350191037)
170. Daviskas E, Anderson SD. Hyperosmolar agents and clearance of mucus in the diseased airway. J Aerosol Med 2006;19(1):100-9
171. Daviskas E, Bilton D, Jacques A, et al. A randomised controlled trial of inhaled mannitol in patients with bronchiectasis. Respirology 2009;14(Suppl 1):A29
172. Pinner NA, Hamilton LA, Hughes A. Roflumilast: a Phosphodiesterase-4 Inhibitor for the Treatment of Severe Chronic Obstructive Pulmonary Disease. Clin Ther 2012;34(1):56-66
173. Fabbri LM, Begh, B, Yasothan U, Kirkpatrick P. Roflumilast. Nat Rev Drug Discov 2010;9(10):761-2
174. Nicholls DJ, Tomkinson NP, Wiley KE, et al. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 2008;74(5):1193-202
175. Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009;121(1):55-68
176. Available from: http://www news bayer com/baynews/baynews nsf/id/Global-Phase-II-study-showed-inhaled-Ciprofloxacin-DPI-Bayer- significantlybetter-reducing-total?Open&ccm=001 2012 [Assessed 8 April 2012]
177. Available from: http://investor aradigm com/releasedetail cfm?releaseid=585430 2012 [Accessed 15 April 2012]
178. Chiu AG, Chen B, Palmer JN, et al. Safety evaluation of sinus surfactant solution on respiratory cilia function. Int Forum Allergy Rhinol 2011;1(4):280-3
179. Matera MG, Calzetta L, Segreti A, Cazzola M. Emerging drugs for chronic obstructive pulmonary disease. Expert Opin Emerg Drugs 2012;17(1):61-82
180. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010;19(5):330-8
181. Ip M, Lam WK, Chan JC, Liong E. Systemic effects of inflammation in bronchiectasis. Respir Med 1991;85(6):521-5
182. Zarogoulidis P, Papanas N, Kioumis I, et al. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2011. [Epub ahead of print]
183. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 2010;36(3):646-54
184. Starner TD, Shrout JD, Parsek MR, et al. Subinhibitory Concentrations of azithromycin decrease nontypeable haemophilus influenzae biofilm formation and diminish established biofilms. Antimicrob Agents Chemother 2008;52(1):137-45
185. Available from: www uspto gov/web/patents/patog/week51/OG/html/1373-3/ US08080529-20111220 html 2012
186. Tandon MK, Phillips M, Waterer G, et al. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest 2010;137(4):805-11
187. Foxwell AR, Cripps AW, Dear KB. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev 2006(4):CD001958
188. Field CE. Bronchiectasis in childhood: II. Aetiology and pathogenesis, including a survey of 272 cases of doubtful irreversible bronchiectasis. Pediatrics 1949;4(2):231-48
189. Marchant JM, Masters IB, Taylor SM, et al. Evaluation and outcome of young children with chronic cough. Chest 2006;129(5):1132-41
190. Kompare M, Weinberger M. Protracted bacterial bronchitis in young children: association with Airway Malacia. J Pediatr 2012;160(1):88-92
191. Wurzel D, Marchant JM, Masters IB, et al. Risk for development of bronchiectasis in patients with Protracted Bacterial Bronchitis. Respirology 2011;16(Suppl 1):A72
192. Marchant JM, Masters IB, Champion A, et al. Randomised controlled trial of amoxycillin-clavulanate in children with chronic wet cough. Thorax 2012;In press
193. Zgherea D, Mendiratta M, Marcus MG, et al. Bronchoscopic findings in children with chronic wet cough. Pediatrics 2012. [Epub ahead of print]
194. Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):1S-23
195. Gibson PG, Chang AB, Glasgow NJ, et al. CICADA: cough in children and adults: diagnosis and assessment. Australian Cough Guidelines summary statement. Med J Aust 2010;192(5):265-71
196. Kapur N, Masel JP, Watson D, et al. Bronchoarterial ratio on High Resolution CT scan of the chest in children without pulmonary pathology-Need to redefine bronchial dilatation. Chest 2011;139(6):1445-50